Welcome to our dedicated page for Vg Life Sciences SEC filings (Ticker: VGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vg Life Sciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vg Life Sciences's regulatory disclosures and financial reporting.
VG Life Sciences, Inc. filed a Form 10 to register under the Securities Exchange Act of 1934 pursuant to Section 12(g) and to become a reporting company.
The company describes itself as a shell with no ongoing operations or revenue, no cash on hand and a working capital deficit of $3,393,105 as of September 30, 2025. Management seeks to identify and acquire an operating business; there are no target negotiations underway. Auditors have expressed substantial doubt about the company’s ability to continue as a going concern. Recent operating results show net losses, including a $170,823 loss for the three months ended September 30, 2025 and a nine-month net loss of $554,904.